OBJECTIVE: C677T and A1298C polymorphisms in the enzyme methylenetetrahydrofolate reductase (MTHFR) have been associated with increased cardiovascular (CV) events in non-rheumatoid arthritis (RA) populations. We investigated potential associations of MTHFR polymorphisms and use of methotrexate (MTX) with time-to-CV event in data from the Veterans Affairs Rheumatoid Arthritis (VARA) registry. METHODS: VARA participants were genotyped for MTHFR polymorphisms. Variables included demographic information, baseline comorbidities, RA duration, autoantibody status, and disease activity. Patients' comorbidities and outcome variables were defined using International Classification of Diseases-9 and Current Procedural Terminology codes. The combined CV event outcome included myocardial infarction (MI), percutaneous coronary intervention, coronary artery bypass graft surgery, and stroke. Cox proportional hazards regression was used to model the time-to-CV event. RESULTS: Data were available for 1047 subjects. Post-enrollment CV events occurred in 97 patients (9.26%). Although there was a trend toward reduced risk of CV events, MTHFR polymorphisms were not significantly associated with time-to-CV event. Time-to-CV event was associated with prior stroke (HR 2.01, 95% CI 1.03-3.90), prior MI (HR 1.70, 95% CI 1.06-2.71), hyperlipidemia (HR 1.57, 95% CI 1.01-2.43), and increased modified Charlson-Deyo index (HR 1.23, 95% CI 1.13-1.34). MTX use (HR 0.66, 95% CI 0.44-0.99) and increasing education (HR 0.87, 95% CI 0.80-0.95) were associated with a lower risk for CV events. CONCLUSION: Although MTHFR polymorphisms were previously associated with CV events in non-RA populations, we found only a trend toward decreased association with CV events in RA. Traditional risk factors conferred substantial CV risk, while MTX use and increasing years of education were protective.
OBJECTIVE:C677T and A1298C polymorphisms in the enzyme methylenetetrahydrofolate reductase (MTHFR) have been associated with increased cardiovascular (CV) events in non-rheumatoid arthritis (RA) populations. We investigated potential associations of MTHFR polymorphisms and use of methotrexate (MTX) with time-to-CV event in data from the Veterans Affairs Rheumatoid Arthritis (VARA) registry. METHODS: VARA participants were genotyped for MTHFR polymorphisms. Variables included demographic information, baseline comorbidities, RA duration, autoantibody status, and disease activity. Patients' comorbidities and outcome variables were defined using International Classification of Diseases-9 and Current Procedural Terminology codes. The combined CV event outcome included myocardial infarction (MI), percutaneous coronary intervention, coronary artery bypass graft surgery, and stroke. Cox proportional hazards regression was used to model the time-to-CV event. RESULTS: Data were available for 1047 subjects. Post-enrollment CV events occurred in 97 patients (9.26%). Although there was a trend toward reduced risk of CV events, MTHFR polymorphisms were not significantly associated with time-to-CV event. Time-to-CV event was associated with prior stroke (HR 2.01, 95% CI 1.03-3.90), prior MI (HR 1.70, 95% CI 1.06-2.71), hyperlipidemia (HR 1.57, 95% CI 1.01-2.43), and increased modified Charlson-Deyo index (HR 1.23, 95% CI 1.13-1.34). MTX use (HR 0.66, 95% CI 0.44-0.99) and increasing education (HR 0.87, 95% CI 0.80-0.95) were associated with a lower risk for CV events. CONCLUSION: Although MTHFR polymorphisms were previously associated with CV events in non-RA populations, we found only a trend toward decreased association with CV events in RA. Traditional risk factors conferred substantial CV risk, while MTX use and increasing years of education were protective.
Authors: Mariska Klerk; Petra Verhoef; Robert Clarke; Henk J Blom; Frans J Kok; Evert G Schouten Journal: JAMA Date: 2002 Oct 23-30 Impact factor: 56.272
Authors: Jeffrey R Curtis; Archana Jain; Johan Askling; S Louis Bridges; Loreto Carmona; William Dixon; Axel Finckh; Kimme Hyrich; Jeffrey D Greenberg; Joel Kremer; Joachim Listing; Kaleb Michaud; Ted Mikuls; Nancy Shadick; Daniel H Solomon; Michael E Weinblatt; Fred Wolfe; Angela Zink Journal: Semin Arthritis Rheum Date: 2010-08 Impact factor: 5.532
Authors: Herbert C Szeto; Robert K Coleman; Parisa Gholami; Brian B Hoffman; Mary K Goldstein Journal: Am J Manag Care Date: 2002-01 Impact factor: 2.229
Authors: Sarah L Westlake; Alexandra N Colebatch; Janis Baird; Patrick Kiely; Mark Quinn; Ernest Choy; Andrew J K Ostor; Christopher J Edwards Journal: Rheumatology (Oxford) Date: 2009-11-27 Impact factor: 7.580
Authors: B J Radovits; D A Popa-Diaconu; C Popa; A Eijsbouts; R F J M Laan; P L C M van Riel; J Fransen Journal: Ann Rheum Dis Date: 2008-08-13 Impact factor: 19.103
Authors: Joshua F Baker; Grant W Cannon; Said Ibrahim; Candace Haroldsen; Liron Caplan; Ted R Mikuls Journal: J Rheumatol Date: 2015-04-01 Impact factor: 4.666
Authors: Joshua F Baker; Bryant R England; Ted R Mikuls; Harlan Sayles; Grant W Cannon; Brian C Sauer; Michael D George; Liron Caplan; Kaleb Michaud Journal: Arthritis Care Res (Hoboken) Date: 2018-12 Impact factor: 4.794
Authors: Joshua F Baker; Erica Billig; Kaleb Michaud; Said Ibrahim; Liron Caplan; Grant W Cannon; Andrew Stokes; Vikas Majithia; Ted R Mikuls Journal: Arthritis Rheumatol Date: 2015-07 Impact factor: 10.995
Authors: Joshua F Baker; Brian C Sauer; Grant W Cannon; Chia-Chen Teng; Kaleb Michaud; Said Ibrahim; Erik Jorgenson; Lisa Davis; Liron Caplan; Amy Cannella; Ted R Mikuls Journal: Arthritis Rheumatol Date: 2016-08 Impact factor: 10.995
Authors: Joshua F Baker; Bryant R England; Michael George; Grant Cannon; Brian Sauer; Alexis Ogdie; Bartlett C Hamilton; Carlos Hunter; Michael J Duryee; Geoffrey Thiele; Ted R Mikuls Journal: Ann Rheum Dis Date: 2021-01-04 Impact factor: 19.103
Authors: Tate M Johnson; Harlan R Sayles; Joshua F Baker; Michael D George; Punyasha Roul; Cheng Zheng; Brian Sauer; Katherine P Liao; Daniel R Anderson; Ted R Mikuls; Bryant R England Journal: Ann Rheum Dis Date: 2021-05-28 Impact factor: 19.103